Published in Gene Therapy Weekly, July 13th, 1998
The test if manufactured by Zeneca Diagnostics, Wilmington, Delaware, and detects gene abnormalities associated with bowel, pancreatic and lung cancers. Widespread interest is expected after its debut at the joint meeting of the British and Irish Associations for Cancer Research in Dublin, Ireland, June 21-23, 1998.
Elucigene K-RAS7, which uses Zeneca Diagnostics' proprietary Amplification Refractory Mutation System (ARMS) technology, detects seven frequently found mutations in the Kirsten ras oncogene. The test offers superior levels of sensitivity allowing clinicians to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.